Background: Using patient-reported and objective assessment tools, we sought to quantify cognitive symptoms and objective cognitive dysfunction in patients irradiated for skull base cancer.
Results: Of the 122 participants analyzed, the majority (63%) had no frank detectable cognitive impairment by TICS, with frank impairment in 6%. Overall, mean patient-reported problems with memory (MDASI memory ) was 3.3 (SD 62.66). On recursive partition analysis, the MDASI memory cutoff point of 5 was associated with detectable cognitive impairment by TICS (logworth 1.69; P 5 .02), yet no MDASImemory threshold was associated with unambiguous absence of impairment by TICS. Conclusion: Approximately one third of patients had ambiguous results by TICS assessment, for whom more rigorous testing may be warranted. Moderate to severe levels of patient-reported memory complaints on the MDASI-HN module may have utility as a screening tool for cognitive dysfunction in this population.
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I NT ROD UCTI ON
Cognitive deficits have been well described in patients who received chemotherapy and/or radiotherapy (RT) for malignancies affecting the central nervous system (CNS). [1] [2] [3] [4] Verbal and spatial memory, attention, and problem-solving capacity can be impacted in up to 90% of those who receive whole brain irradiation. 5 Minimizing the RT-attributable cognitive impact has become increasingly emphasized in both clinical and research investigations. Much of this scientific work to date has focused on patients with intracranial malignancies (ie, in which brain parenchyma is a de facto RT target). There has been relatively little emphasis given to the long-term cognitive outcomes in patients treated for extracranial tumors near the skull base, where numerous critical CNS structures can receive incidental yet substantial radiation doses. 6, 7 Although RT techniques, namely intensity-modulated radiotherapy (IMRT), have become increasingly more conformal, the beam arrangements required traverse normal tissues that were virtually unirradiated in previous techniques. The associated increase in lower and intermediate doses to certain CNS structures from IMRT led to observed increases in selected acute effects of treatment, the so-called "beam path toxicity." 8 However, the long-term cognitive function and patient perception of memory disturbance in head and neck cancer survivors, which may at least in part be due to the incidental RT dose to the CNS, has not been well defined.
To this end, we surveyed long-term head and neck cancer survivors who received RT to the skull base using the Telephone Interview for Cognitive Status (TICS), 9 an objective screening measure for cognitive impairment and the MD Anderson Symptom Inventory-Head and Neck module (MDASI-HN), 10 a patient-reported multisymptom assessment tool that includes a memory-related item. The specific purposes of this study were to quantify and correlate patientreported and objective cognitive function in a subset of head and neck cancer survivors previously irradiated to the skull base, and to identify relevant thresholds of patient-reported problems with memory to serve as a cognitive impairmentscreening tool using a telephone or electronically deliverable survey.
M ATE RI ALS AN D ME THO DS

Study design
This cross-sectional questionnaire-based study was conducted after approval from the Institutional Review Board at The University of Texas MD Anderson Cancer Center. Adult head and neck cancer survivors, able to read and understand English, and with no pretreatment clinically overt cognitive impairment were eligible. Those who received more than one course of RT to the head and neck or who had a history of brain metastases were excluded. Participants considered for this analysis were those previously irradiated at our institution for a diagnosis of nasopharyngeal, nasal cavity, or paranasal sinus cancer, or those with a salivary gland cancer in which a skull base RT target was included. Electronic medical records for patients treated with RT at our institution between October 2001 and June 2013 were retrospectively reviewed and basic patient demographic information and clinical variables extracted. Participants were assessed using both the TICS and MDASI-HN, which were both administered by telephone interview from May 2014 until August 2014.
Study assessments
The TICS survey is a concise, standardized examination of cognitive functioning designed to be delivered over the The TICS has a high test-retest reliability, and its sensitivity and specificity for detecting frank cognitive impairment are well established. 9, 11 Likewise, the MDASI-HN is a validated patient-reported multisymptom assessment tool. The questionnaire contains 28 items, including 13 "core" symptom items, 9 "head and neck cancer-specific" symptom items, as well as 6 items measuring how these 22 symptoms interfere with activities of daily life. 10 The MDASI-HN items are rated by patients on a 0-10 severity scale. For the purposes of this study, we considered the single MDASI-HN symptom item "problem remembering things" (MDASI memory ) and the total MDASI-HN 22 symptom composite score (MDASI composite ).
Statistical analysis
The TICS and MDASI-HN scores were tabulated. Patients were stratified into TICS categorical cohorts according to instrument guidelines (eg, >32 "Unimpaired"; 26-32 "Ambiguously impaired"; 21-25 "Mildly impaired"; and <21 "Moderately/severely impaired"). Additionally, TICS performance was dichotomized as a 2 categorical variable, one whereby TICS scores <26 were categorized as demonstrating detectable frank cognitive dysfunction ("Detectably Impaired") and scores >26 are considered "Without definitive cognitive impairment." In order to investigate potential relationships between objective cognitive performance, patient perception of problems with memory, and overall symptom burden, Wilcoxon rank sum analysis of TICS, MDASI memory , and MDASI composite scores were performed. We investigated proportional relationships using contingency tables, with Fisher's correction for bins of <10 patients per cohort.
To define a threshold value of the MDASI memory item associated with objective cognitive performance, we used recursive-partitioning analysis (RPA) to choose a "cutoff point" best represented by our sample of those with frank cognitive impairment (ie, TICS <26). The RPA allows selection of the "thresholds" for ordinal/continuous variables using a binary categorization variable. The RPA is especially suited to scenarios in which it is desirable to select and "threshold" continuous variable(s) associated with a categorical variable in the context of a multitude of predictor variables, even in the presence of complex interactions between candidate covariates. 12 We performed a decision tree RPA, with iterative partitions (with a prespecified minimum grouping of 13 patients per split/partition and a 20% holdback learning set) performed until a split demonstrated a logworth value greater than the equivalent Bonferroni corrected P < .05 (ie, the first a priori split criteria was set at a logworth <1.30/P < .05, the second split at logworth <1.6/P < .025, and the third split logworth <1.78/P < .016, etc), with pruning after nonsignificance, to distill candidate MDASI memory item thresholds. Split confirmation was achieved using iterative bootstrap forest repetition for split confirmation, with 1000 iterative splits performed, prespecifying a single term per split, with a 13-patient minimum split leaf/bin, and 20% holdback. After split completion/pruning, a receiver operator characteristic (ROC) curve was created to determine discriminatory performance with 10-fold cross-validation to assess overfitting/model generalizability. After MDASI memory item thresholding by RPA, cross-tabulation and Wilcoxon ranksum measures were used to evaluate relationships between constructed binary TICS and MDASI memory cohorts. A nonBonferroni corrected P 5 .05 was selected for all significance measures (excepting RPA, vide supra) in this exploratory analysis. Univariate logistic regression analysis was done to investigate the correlation of the following covariates: educational level (no college education vs college education and higher), age (binary with thresholding by RPA at age 57 years), race (white vs non-white), sex (male vs female), T classification (early [T1-T2] vs advanced), subsite of origin (nasopharynx vs others), chemotherapy (chemotherapy vs no chemotherapy), receipt of skull base surgery (skull base surgery vs no skull base surgery), radiation dose (as a continuous variable), and radiation technique (3D-conformal RT vs IMRT). Variables with P values 0.2 were then added in a multivariate logistic regression model. All statistics were performed with JMP Pro 11 (SAS Institute, Cary, NC).
R ES ULT S
One hundred thirty-one patients participated in this aspect of the study. Of these, 9 patients were excluded; 3 because of receipt of multiple separate courses of RT to the head and neck, 3 because of prior treatment for brain metastases, 2 because of clinically evident cognitive impairment before treatment start, and 1 because of receipt of RT that did not include the skull base. Thus, 122 participants formed the cohort. Table 1 summarizes the patient demographics, diseases, and the treatment characteristics. Eighty-seven patients (71%) received prior systemic therapy. Of those, 72 (83%) received concurrent platinum-based regimens.
Mean MDASI composite score for the entire cohort was 46.3 (SD 634.4) and the mean MDASI memory was 3.3 (SD 62.7). Regarding TICS results, the proportion of participants by cognitive performance are shown in Figure 1 . In the group with definitive impairment (TICS <26), mean MDA-SI composite and MDASI memory scores were 71.3 (SD 645.2) and 5.1 (SD 62.8), respectively. Bivariate analysis of TICS overall score to MDASI memory scores revealed that lower TICS scores were associated with increased MDASI memory scores (P < .009) and MDASI composite scores (P < .034) as numerical scales; use of binary impairment threshold of TICS >26 showed numerically higher rates of impairment based on MDASI memory scoring, but did not demonstrate statistical significance (P 5 .057; Figure 2 ). The RPA revealed that a MDASI memory cutoff point of 4/ 10 was statistically associated with discrimination of those with detectable cognitive impairment by TICS (logworth 1.55; P 5 .028), with 10-fold cross-validation showing this split as acceptable, with resultant ROC and 20% holdback validation curve shown in Figure 3 . The ROC analysis showed an area under the curve (AUC) of 0.78 (asymptotic 95% AUC confidence interval [CI] 0.53-0.91; asymptotic significance of P 5 .04, where H 0 denotes AUC 5 0.5) suggesting acceptable discriminative capacity for MDASI memory threshold of 5 in determining whether patients are cognitively impaired (ie, scoring <26 points) by TICS assessment.
Post hoc testing revealed that no significant split could be found on RPA to discriminate patients who were unimpaired by TICS criteria (ie, TICS >32). This suggests that, although a score of 5 or more on the MDASI memory single item can potentially identify frank impairment (eg, "rule in"), it could not be as useful classifying whether patients are unambiguously unimpaired ("rule out"). Further, those with detectable impairment (TICS <26) had a mean MDASI composite score of 71.3 (SD 645.2), whereas those without impairment (TICS >32) reported a mean MDASI composite score of 43.1 (SD 631.44; P value < .001). Separate analysis investigating the difference of TICS, MDASI composite , and MDASImemory scores by radiation treatment technique (IMRT vs 3D-conformal RT) failed to identify any significant difference among reported scores.
Univariate analysis revealed that lack of any college education (odds ratio [OR] 20.08; P < .007) and non-white race (OR 9.00; P 5 .007) were both associated with impaired TICS scores. Multivariate analysis revealed both variables to be independently associated with impaired TICS scores ( Table 2 ). Further inquiry is necessary to reinforce these findings, but, at present, these findings may inform clinicians in making future RT decisions involving patients with skull base, nasal cavity, or nasopharyngeal cancers.
D IS C US S I ON
Most prior publications have focused on cognitive deficits in patients undergoing CNS irradiation. This is one of the largest studies focusing on patients with head and neck cancer receiving skull base irradiation with incidental CNS radiation exposure. In addition to the potential impact on cognitive function, the incidental dose delivered to CNS structures has been shown to have impact on CNS-related symptoms. Radiation-associated nausea and vomiting symptoms were observed more frequently in patients with a higher mean dose of radiation to certain nausea/vomiting-associated regions of interest that could coincide with the nontargeted CNS exposure when irradiating head and neck tumors. 8 Additionally, fatigue during head and neck RT has been observed more frequently in patients receiving IMRT compared with conventional RT techniques 13 and a higher mean RT dose to nontargeted CNS tissues. 14, 15 Previous studies investigating cognitive function after RT for head and neck cancers have been generally limited by small patient numbers, a m elange of sites with differing brain proximity (eg, skull base, larynx, and hypopharynx), short follow-up (ie, short interval from completion of RT to cognitive assessment), and use of historical RT techniques.
These studies are outlined in the Supporting Information Table S1 .
In contrast, our cohort studied over 100 patients with extended follow-up and modern RT techniques, as the majority received IMRT. More specifically, our study targeted survivors of skull base or nasopharyngeal malignancies, a cohort who would have received higher incidental radiation doses to CNS structures compared to non-skull base head and neck cancer subsets. Our data demonstrate that 6% of the patient population was found to have some level of frank cognitive impairment, either "impaired" or "severely impaired," using the TICS screening tool. Additionally, 37% of patients were classified as "ambiguous" by TICS assessment. Certain inherent limitations to the TICS tool could affect the patients' abilities to appropriately complete this instrument. For example, the TICS is delivered verbally via telephone and completion is impacted on the patients' hearing acuity, English fluency, as well as attention span in order to complete this survey. 11 Furthermore, the instrument is primarily validated and used patients with Alzheimer's and traumatic brain injury and not specifically validated in patients with head and neck cancer. Nonetheless, given the need to assess long-term cancer survivors who are not readily available for in-clinic assessments, TICS represents an assessment tool that allows rapid large-scale patient screening/assessment.
11
Importantly, our data also indicate in a cross-sectional dataset that a single item patient-reported memory question (MDASI memory) functioned as a potential discriminator of patients with frank cognitive impairment, as detected by TICS score <26. However, no threshold in patientreported memory problems could be identified to effectively discriminate between patients who were not cognitively impaired versus those with "ambiguous" impairment. Therefore, the MDASI-HN memory item might serve as a simple single-item screening tool for frank cognitive impairment for similar cohorts in long-term follow-up in analogous populations.
Our results also showed that higher education level might be protective from development of frank cognitive impairments in this cohort. This effect has been demonstrated in noncancer patient populations (ie, Parkinson's 16 and dementia 17 ) with considerable consistency. Some research suggests education level affords this protective effect on language domains but not on visuospatial/executive functions, naming, attention, and other cognitive functions. 18 However, little research currently exists to explain the protective cognitive effects increased educational attainment might afford to patients with cancer receiving RT. Our study has limitations, including the cohort of patients classified as "ambiguous" by TICS assessment. Characterization of this "ambiguous" subset would require further detailed cognitive assessment, as they could be experiencing radiation-attributable yet undetectable levels of cognitive impairment by the assessment used in this study. Serial and longitudinal assessment would also be valuable, as treatment-related cognitive impairment could worsen over time. Further, no baseline pretherapy assessment of TICS or MDASI-HN was performed in this cross-sectional late toxicity assessment dataset. In addition, no objective memory testing was performed. Future studies will seek to incorporate baseline assessment and longitudinal changes. Moreover, despite we did not find a significant correlation between radiation prescription dose/technique and impaired TICS scores in this study, efforts to interrogate dose-response relationship between functional scores and radiation dose to specific brain regions of interest (eg, hippocampus) are required to establish dose-toxicity relationship and potential dose constraint for future radiation plans. Nonetheless, this study represents, to our knowledge, the largest cross-sectional assessment of dual subjective and objective cognitive status in patients with skull base cancer who were largely treated with modern RT approaches.
C ONCL US I ONS
Detectable cognitive impairment was observed in the minority, but approximately one third of patients had ambiguous results by TICS, for whom more rigorous testing would be required to completely characterize. Single-item MDASI memory patient-reported memory problem could serve as a simple screening tool to identify those with potential cognitive impairment. Future studies are required to define mechanism of change/injury, risk and protective factors, temporal kinetics of cognitive alteration after skull base RT, and to define radiation dose-response relationships for key CNS structures and late cognitive decline. Additionally, future prospective studies will aim to validate the findings reported in this study.
